Telix Pharmaceuticals Limited
ASX: TLX
Strong Illuccix demand and portfolio expansion drive Telix’s robust revenue growth.
(Source: TradingView) 3-Month Performance Profile of TLX on a DTF compared to S&P/ASX 200 (XJO).
Telix reported a 69.02% year-on-year increase in revenue to $615.34 million for the first half of FY2025, reflecting strong execution across its commercial portfolio. Cash r
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
